Published ahead of print on October 22, 2004, doi:10.1164/rccm.200409-1164OC
American Journal of Respiratory and Critical Care Medicine Vol 171. pp. 261-268, (2005)
© 2005 American Thoracic Society
doi: 10.1164/rccm.200409-1164OC
CXCL11 Attenuates Bleomycin-induced Pulmonary Fibrosis via Inhibition of Vascular Remodeling
Marie D. Burdick*,
Lynne A. Murray*,
Michael P. Keane,
Ying Ying Xue,
David A. Zisman,
John A. Belperio and
Robert M. Strieter
Division of Pulmonary and Critical Care Medicine, Department of Medicine, and Departments of Pediatrics and Pathology and Laboratory Medicine, UCLA School of Medicine, Los Angeles, California
Correspondence and requests for reprints should be addressed to Robert M. Strieter, M.D., Division of Pulmonary and Critical Care Medicine, Department of Medicine, David Geffen School of Medicine at UCLA, 14-154 Warren Hall, 900 Veteran Avenue, Los Angeles, CA 900951786. E-mail: rstrieter{at}mednet.ucla.edu
Aberrant vascular remodeling is a central hallmark for the development and progression of idiopathic pulmonary fibrosis. The mechanisms underlying the pathophysiologic alterations, however, are poorly understood. A recent phase II trial of interferon -1b has demonstrated a trend toward a decrease in profibrotic and proangiogenic biologic markers, and upregulation of lung CXCL11 mRNA and bronchoalveolar lavage fluid and plasma protein levels of CXCL11. We hypothesized that net aberrant vascular remodeling seen during the pathogenesis of fibroplasia and deposition of extracellular matrix during bleomycin-induced pulmonary fibrosis can be attenuated by treatment with the angiostatic ELR CXC chemokine, CXCL11. In a preclinical model, systemic administration of CXCL11 reduced pulmonary collagen deposition, procollagen gene expression, and histopathologic fibroplasia and extracellular matrix deposition in the lung of bleomycin-treated mice. CXCL11 treatment significantly reduced bleomycin-induced pulmonary fibrosis without altering specific lung leukocyte populations. CXCR3 is not expressed on fibroblasts and CXCL11 had no direct functional effect on pulmonary fibroblasts. The angiogenic activity in the lung was significantly decreased, however, and CXCL11 treatment reduced the total number of endothelial cells in the lung following bleomycin exposure. The results suggest that CXCL11 inhibits pulmonary fibrosis by altering aberrant vascular remodeling.
Key Words: angiogenesis chemokines fibrosis
This article has been cited by other articles:

|
 |

|
 |
 
M. P. Keane
The role of chemokines and cytokines in lung fibrosis
Eur. Respir. Rev.,
December 1, 2008;
17(109):
151 - 156.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. C. Keeley, B. Mehrad, and R. M. Strieter
Chemokines as Mediators of Neovascularization
Arterioscler. Thromb. Vasc. Biol.,
November 1, 2008;
28(11):
1928 - 1936.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. N. Ajuebor, Y. Jin, G. L. Gremillion, R. M. Strieter, Q. Chen, and P. A. Adegboyega
{gamma}{delta}T Cells Initiate Acute Inflammation and Injury in Adenovirus-Infected Liver via Cytokine-Chemokine Cross Talk
J. Virol.,
October 1, 2008;
82(19):
9564 - 9576.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Hamada, T. Maeyama, T. Kawaguchi, M. Yoshimi, J. Fukumoto, M. Yamada, S. Yamada, K. Kuwano, and Y. Nakanishi
The Role of High Mobility Group Box1 in Pulmonary Fibrosis
Am. J. Respir. Cell Mol. Biol.,
October 1, 2008;
39(4):
440 - 447.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Matsuda, S. Fukuda, K. Matsumoto, and H. Saito
Th1/Th2 Cytokines Reciprocally Regulate In Vitro Pulmonary Angiogenesis via CXC Chemokine Synthesis
Am. J. Respir. Cell Mol. Biol.,
February 1, 2008;
38(2):
168 - 175.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Konigshoff, A. Wilhelm, A. Jahn, D. Sedding, O. V. Amarie, B. Eul, W. Seeger, L. Fink, A. Gunther, O. Eickelberg, et al.
The Angiotensin II Receptor 2 Is Expressed and Mediates Angiotensin II Signaling in Lung Fibrosis
Am. J. Respir. Cell Mol. Biol.,
December 1, 2007;
37(6):
640 - 650.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. J. Scotton and R. C. Chambers
Molecular Targets in Pulmonary Fibrosis: The Myofibroblast in Focus
Chest,
October 1, 2007;
132(4):
1311 - 1321.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Zhang, W. E. Lawson, V. V. Polosukhin, A. Pozzi, T. S. Blackwell, Y. Litingtung, and C. Chiang
Inhibitor of Differentiation 1 Promotes Endothelial Survival in a Bleomycin Model of Lung Injury in Mice
Am. J. Pathol.,
October 1, 2007;
171(4):
1113 - 1126.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Kass, R. S. Bridges, A. Borczuk, and S. Greenberg
Methionine Aminopeptidase-2 as a Selective Target of Myofibroblasts in Pulmonary Fibrosis
Am. J. Respir. Cell Mol. Biol.,
August 1, 2007;
37(2):
193 - 201.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Struyf, M. D. Burdick, E. Peeters, K. Van den Broeck, C. Dillen, P. Proost, J. Van Damme, and R. M. Strieter
Platelet Factor-4 Variant Chemokine CXCL4L1 Inhibits Melanoma and Lung Carcinoma Growth and Metastasis by Preventing Angiogenesis
Cancer Res.,
June 15, 2007;
67(12):
5940 - 5948.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. Dell'Aica, R. Niero, F. Piazza, A. Cabrelle, L. Sartor, C. Colalto, E. Brunetta, G. Lorusso, R. Benelli, A. Albini, et al.
Hyperforin Blocks Neutrophil Activation of Matrix Metalloproteinase-9, Motility and Recruitment, and Restrains Inflammation-Triggered Angiogenesis and Lung Fibrosis
J. Pharmacol. Exp. Ther.,
May 1, 2007;
321(2):
492 - 500.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. D. Nathan, P. W. Noble, and R. M. Tuder
Idiopathic Pulmonary Fibrosis and Pulmonary Hypertension: Connecting the Dots
Am. J. Respir. Crit. Care Med.,
May 1, 2007;
175(9):
875 - 880.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. U. Wells and C. M. Hogaboam
Update in Diffuse Parenchymal Lung Disease 2006
Am. J. Respir. Crit. Care Med.,
April 1, 2007;
175(7):
655 - 660.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Mohsenin, M. D. Burdick, J. G. Molina, M. P. Keane, and M. R. Blackburn
Enhanced CXCL1 production and angiogenesis in adenosine-mediated lung disease
FASEB J,
April 1, 2007;
21(4):
1026 - 1036.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Indraccolo, U. Pfeffer, S. Minuzzo, G. Esposito, V. Roni, S. Mandruzzato, N. Ferrari, L. Anfosso, R. Dell'Eva, D. M. Noonan, et al.
Identification of Genes Selectively Regulated by IFNs in Endothelial Cells
J. Immunol.,
January 15, 2007;
178(2):
1122 - 1135.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. V. Yang, L. H. Burch, M. P. Steele, J. D. Savov, J. W. Hollingsworth, E. McElvania-Tekippe, K. G. Berman, M. C. Speer, T. A. Sporn, K. K. Brown, et al.
Gene Expression Profiling of Familial and Sporadic Interstitial Pneumonia
Am. J. Respir. Crit. Care Med.,
January 1, 2007;
175(1):
45 - 54.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
O.J. Dempsey, K.M. Kerr, L. Gomersall, H. Remmen, and G.P. Currie
Idiopathic pulmonary fibrosis: an update
QJM,
October 1, 2006;
99(10):
643 - 654.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. J. Martinez and M. P. Keane
Update in diffuse parenchymal lung diseases 2005.
Am. J. Respir. Crit. Care Med.,
May 15, 2006;
173(10):
1066 - 1071.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. N. Gomperts and R. M. Strieter
CXC Chemokines in Angiogenesis and Metastases
Am. Assoc. Cancer Res. Educ. Book,
April 1, 2006;
2006(1):
11 - 18.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Pan, M. D. Burdick, J. A. Belperio, Y. Y. Xue, C. Gerard, S. Sharma, S. M. Dubinett, and R. M. Strieter
CXCR3/CXCR3 Ligand Biological Axis Impairs RENCA Tumor Growth by a Mechanism of Immunoangiostasis
J. Immunol.,
February 1, 2006;
176(3):
1456 - 1464.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Pignatti, G. Brunetti, D. Moretto, M.-R. Yacoub, M. Fiori, B. Balbi, A. Balestrino, G. Cervio, S. Nava, and G. Moscato
Role of the Chemokine Receptors CXCR3 and CCR4 in Human Pulmonary Fibrosis
Am. J. Respir. Crit. Care Med.,
February 1, 2006;
173(3):
310 - 317.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Agostini and C. Gurrieri
Chemokine/Cytokine cocktail in idiopathic pulmonary fibrosis.
Proceedings of the ATS,
January 1, 2006;
3(4):
357 - 363.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. M. Strieter
Pathogenesis and Natural History of Usual Interstitial Pneumonia: The Whole Story or the Last Chapter of a Long Novel
Chest,
November 1, 2005;
128(5_suppl_1):
526S - 532S.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2005 American Thoracic Society
|
|
|